AQR Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

AQR Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,965	Closed	-$855K	–	2323
2023 Q1	$855K	Sell	7,965 -1,800	-18%	-$207K	﹤0.01%	1605
2022 Q4	$1.07M	Buy	9,765 +1,416	+17%	+$91.8K	﹤0.01%	1540
2022 Q3	$493K	Buy	+8,349	New	+$382K	﹤0.01%	1789

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

AQR Capital Management's RXDX Position: Q2 2023 in Review

AQR Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 7,965 shares — an estimated $855K sold.

AQR Capital Management first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $1.07M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

AQR Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
AQR Capital Management sold 7,965 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $855K.
AQR Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
AQR Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $1.07M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on AQR Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.